President-elect Donald Trump\u2019s choice to run the sprawling government agency that administers Medicare, Medicaid, and the Affordable Care Act marketplace \u2014 celebrity doctor Mehmet Oz \u2014 recently held broad investments in health care, tech, and food companies that would pose significant conflicts of interest.<\/p>\n
Oz\u2019s holdings, some shared with family, included a stake in UnitedHealth Group worth as much as $600,000, as well as shares of pharmaceutical firms and tech companies with business in the health care sector, such as Amazon. Collectively, Oz\u2019s investments total tens of millions of dollars, according to financial disclosures he filed during his failed 2022 run for a Pennsylvania U.S. Senate seat.<\/p>\n
Trump said Tuesday he would nominate Oz as administrator of the Centers for Medicare & Medicaid Services. The agency\u2019s scope is huge: CMS oversees coverage for more than 160 million Americans, nearly half the population. Medicare alone<\/a> accounts for approximately $1 trillion in annual spending, with over 67 million enrollees.<\/p>\n
\u201cIt\u2019s obvious that over the years he\u2019s cultivated an interest in the pharmaceutical industry and the insurance industry,\u201d said Peter Lurie, president of the Center for Science in the Public Interest, a watchdog group. \u201cThat raises a question of whether he can be trusted to act on behalf of the American people.\u201d (The publisher of KFF Health News, David Rousseau, is on the CSPI board<\/a>.)<\/p>\n
Oz used his TikTok page on multiple occasions in November to praise Trump and Robert F. Kennedy Jr., including their efforts to take on the \u201cillness-industrial complex,\u201d and he slammed \u201cso-called experts like the big medical societies\u201d for dishing out what he called bad nutritional advice. Oz\u2019s positions on health policy have been chameleonic; in 2010, he cut an ad<\/a> urging Californians to sign up for insurance under President Barack Obama\u2019s Affordable Care Act, telling viewers they had a \u201chistoric opportunity.\u201d<\/p>\n
CMS\u2019 main job is to administer Medicare. About half of new enrollees now choose Medicare Advantage, in which commercial insurers provide their health coverage, instead of the traditional, government-run program, according to an analysis<\/a> from KFF, a health information nonprofit that includes KFF Health News.<\/p>\n
Proponents of Medicare Advantage say the private plans offer more compelling services than the government and better manage the costs of care. Critics note that Medicare Advantage plans have a long history of costing taxpayers more<\/a> than the traditional program.<\/p>\n
UnitedHealth, CVS, and Cigna are all substantial players in the Medicare Advantage market. It\u2019s not always a good relationship with the government. The Department of Justice filed a 2017 complaint against UnitedHealth alleging the company<\/a> used false information to inflate charges to the government. The case is ongoing.<\/p>\n
Oz is an enthusiastic proponent of Medicare Advantage. In 2020, he proposed offering Medicare Advantage to all; during his Senate run, he offered a more general pledge to expand those plans. After Trump announced Oz\u2019s nomination for CMS, Jeffrey Singer, a senior fellow at the libertarian-leaning Cato Institute, said he was<\/a> \u201cuncertain about Dr. Oz\u2019s familiarity with health care financing and economics.\u201d<\/p>\n
Oz has gotten a mixed reception from elsewhere in Washington. Pennsylvania Sen. John Fetterman, the Democrat who defeated Oz in 2022, signaled he\u2019d potentially support his appointment to CMS. \u201cIf Dr. Oz is about protecting and preserving Medicare and Medicaid, I\u2019m voting for the dude,\u201d he said<\/a> on the social platform X.<\/p>\n
Amazon operates an internet pharmacy, and the company announced in June that its subscription service<\/a> is available to Medicare enrollees. It also owns a primary care service<\/a>, One Medical, that accepts Medicare and \u201cselect\u201d Medicare Advantage plans.<\/p>\n
During the Biden administration, Congress gave Medicare authority to negotiate with drug companies over their prices. CMS initially selected 10 drugs. Those drugs collectively accounted for $50.5 billion in spending<\/a> between June 1, 2022, and May 31, 2023, under Medicare\u2019s Part D prescription drug benefit.<\/p>\n
Oz may gain or lose financially from other Trump administration proposals.<\/p>\n
For example, as of 2022, Oz held investments worth as much as $6 million in fertility treatment providers. To counter fears that politicians who oppose abortion would ban in vitro fertilization, Trump floated during his campaign<\/a> making in vitro fertilization treatment free. It\u2019s unclear whether the government would pay for the services.<\/p>\n
KFF Health News<\/a> is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF\u2014an independent source of health policy research, polling, and journalism. Learn more about KFF<\/a>.<\/p>\n
This story can be republished for free (details<\/a>).<\/p>\n","protected":false},"excerpt":{"rendered":"